Leqembi for Alzheimer's: Understanding Dosage, Administration, and Key Information

Understanding Leqembi (Lecanemab-irmb) for Alzheimer's Disease

Alzheimer's disease, a progressive neurodegenerative disorder, affects millions worldwide, impacting memory, thinking, and daily functioning. While the exact cause remains elusive, the accumulation of beta-amyloid plaques in the brain is strongly implicated. Leqembi, a groundbreaking medication also known as lecanemab-irmb, offers a new avenue for treatment by targeting these beta-amyloid plaques. This blog post aims to provide a comprehensive overview of Leqembi, focusing on its dosage, administration, and other crucial aspects relevant to patients and caregivers in India.

What is Leqembi and How Does it Work?

Leqembi is a prescription medication approved for the treatment of Alzheimer's disease, specifically in individuals experiencing mild dementia. It is a monoclonal antibody designed to bind to and help clear beta-amyloid proteins from the brain. By reducing the burden of these plaques, Leqembi aims to slow down the progression of cognitive decline associated with Alzheimer's disease. Clinical studies have shown a reduction in beta-amyloid plaques on PET scans after 13 weeks of Leqembi treatment, suggesting its efficacy in targeting the disease's pathology.

Leqembi Dosage and Administration

The dosage of Leqembi is carefully determined based on a patient's body weight in kilograms (kg). The recommended starting dose is 10 mg/kg, administered intravenously (IV) as an infusion. This infusion is typically given once every two weeks. Your doctor will calculate the precise dose tailored to your individual needs and medical condition.

Forms of Leqembi:

• Intravenous (IV) Infusion: Leqembi is available as a liquid solution in vials, typically in strengths of 100 mg/mL. These vials come in 2-mL or 5-mL sizes. The infusion is administered at your doctor's office or a clinic by a healthcare professional.
• Leqembi IQLIK Autoinjector: For convenience, Leqembi is also available as a single-dose prefilled autoinjector, known as Leqembi IQLIK. This form contains a higher concentration (200 mg/mL) and is administered as a subcutaneous injection (under the skin).

Administering Leqembi IQLIK:

If you are prescribed Leqembi IQLIK, your doctor will guide you on its proper administration. Before injecting, the autoinjector should be removed from the refrigerator and allowed to sit at room temperature for about 20 minutes. It is crucial not to shake the pen. The injection can be given into the abdomen, upper thigh, or the back of the upper arm. Ensure you avoid areas with moles, scars, bruises, tattoos, or any skin that is red, hard, or tender.

What if a Dose is Missed?

Missing a dose of Leqembi should be addressed promptly. If you miss an IV infusion, contact your doctor immediately to schedule the next dose as soon as possible. For Leqembi IQLIK weekly injections, if you miss a dose, take it as soon as you remember, provided it's within 6 days of the missed dose. After taking the missed dose, resume your regular dosing schedule on the next scheduled day.

Leqembi vs. Aricept: A Comparison

It's important to understand how Leqembi differs from other Alzheimer's medications. While both Leqembi and Aricept (donepezil) are used to manage Alzheimer's symptoms, they work differently. Aricept is available as an oral pill taken daily, whereas Leqembi is administered via IV infusion or subcutaneous injection. Leqembi's mechanism of action, focusing on clearing beta-amyloid plaques, is a key distinction.

Potential Side Effects and Management

Like all medications, Leqembi can cause side effects. A significant concern is amyloid-related imaging abnormalities (ARIA), which can manifest as swelling or bleeding in the brain. Your doctor will likely monitor you for ARIA through regular brain scans (MRI). Depending on the severity of ARIA or other side effects, your doctor may temporarily stop Leqembi treatment until the side effect resolves. In some cases, treatment may be resumed at a lower frequency or with adjustments, or an alternative treatment may be recommended.

Preventing Infusion-Related Reactions:

Some individuals may experience reactions during or after an IV infusion. To mitigate this, your doctor might prescribe medications before your infusion. These could include nonsteroidal anti-inflammatory drugs (NSAIDs) or other suitable medications to help prevent infusion-related reactions.

Long-Term Treatment with Leqembi

Leqembi is generally prescribed as a long-term treatment for Alzheimer's disease. If your doctor determines that it is safe and effective for your condition, you will likely continue receiving it for an extended period. The decision to continue treatment is based on ongoing assessment of its benefits and your tolerance to the medication.

When to Consult a Doctor

It is essential to maintain open communication with your healthcare provider throughout your treatment with Leqembi. Consult your doctor immediately if you experience any new or worsening symptoms, such as severe headaches, confusion, vision changes, or any signs of an infusion reaction. Discuss any concerns you have regarding the dosage, administration, or potential side effects. Your doctor is your primary resource for managing your Alzheimer's disease and ensuring the safe and effective use of Leqembi.

Conclusion

Leqembi represents a significant advancement in the treatment of Alzheimer's disease, offering hope to patients and their families. Understanding its dosage, administration, potential side effects, and the importance of regular medical consultation is crucial for optimal outcomes. For individuals in India considering or undergoing Leqembi treatment, this information serves as a guide to navigate the treatment journey with confidence and informed decision-making.